A Study of CS-3150 to Evaluate Safety in Japanese Type 2 Diabetic Patients with Macroalbuminuria
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Esaxerenone (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 27 Nov 2018 Status changed from active, no longer recruiting to completed.
- 20 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Sep 2017 Status changed from not yet recruiting to recruiting.